Results 41 to 50 of about 39,814 (206)

Monitoring Serum Digoxin Concentrations during Digoxin Immune Fab Therapy

, 1991
Measurement of serum digoxin concentrations (SDCs) is used routinely in the diagnosis of digoxin toxicity. Following administration of the antidote, digoxin immune antigen binding fragments (Fab), SDC monitoring is hampered by assay-related problems ...
Paul J. Green, Robert D. Colucci, Peter H. Vlasses, Barbara J. Zarowitz, Doyle M. Cummings, Sylvie Robert, Michael R. Ujhelyi   +6 more
core   +1 more source

MELD score predicts outcomes in patients with advanced heart failure: A longitudinal evaluation

ESC Heart Failure, Volume 12, Issue 2, Page 839-847, April 2025.
Abstract Aims Advanced heart failure (AHF) is characterized by recurrent episodes of haemodynamic instability and frequent hospitalizations, leading to a progressive decline in quality of life and high mortality rates. The objectives of this study were to evaluate the effect of the model for end‐stage liver disease (MELD) score and its variations in ...
Francesco Curcio, Cristiano Amarelli, Rosaria Chiappetti, Irene Mattucci, Veronica Flocco, Mahmoud Issa Rammal, Ciro Abete, Francesca Mazzella, Ciro Maiello, Pasquale Abete, Francesco Cacciatore   +10 more
wiley   +1 more source

Physiologically based pharmacokinetic modelling of acute digoxin toxicity and the effect of digoxin-specific antibody fragments

, 2019
Context: Recommended doses of digoxin-specific antibody fragments (digoxin-Fab) for treatment of acute digoxin poisoning are pharmacokinetically unsubstantiated and theoretically excessive.
Betty S. H. Chan (4169767), Nicholas A. Buckley (238905), Lucy M. Bracken (6458540)   +2 more
core   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Clinical pharmacokinetics of digoxin 1980.

, 1980
The following summarises the contents of both this review and its predecessor in this journal (Iisalo, 1977). The two reviews should be read in conjunction with each other. Digoxin is absorbed mostly from the proximal part of the small intestine.
Aronson, JK, Aronson, Jeffrey
core   +1 more source

Individual dosage of digoxin in patients with heart failure [PDF]

, 2010
After the publication of DIG trial, the therapeutic target of serum digoxin concentration (SDC) for the treatment of heart failure (HF) has been lowered (0.40-1.00?ng/ml). However, the majority of equations to calculate digoxin dosages were developed for
G. Moschovitis, Stricker, H, H. Stricker, H. Brunner-La Rocca, Mombelli, G, Stricker, H., G. Mombelli, Moschovitis, G., Muzzarelli, S., P. Foglia, Foglia, P., Foglia, P, Moschovitis, G, Pfister, O., Stricker, Bruno H, Muzzarelli, S, Pfister, O, Brunner-La Rocca, H.; id_orcid, Mombelli, G., Brunner-La Rocca, H, O. Pfister, S. Muzzarelli, Brunner-La Rocca, H.   +22 more
core   +1 more source

Phenotyping patients with chronic obstructive pulmonary disease and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 900-911, April 2025.
Central illustration. Abbreviations: ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin‐receptor‐neprilysin inhibitor; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; CV, cardiovascular; EF, ejection fraction; eGFR, estimated glomerular ...
Peter Moritz Becher, Felix Lindberg, Lina Benson, Camilla Hage, Ulf Dahlström, Stephan Rosenkranz, Francesco Cosentino, Giuseppe M.C. Rosano, Stefan Blankenberg, Paulus Kirchhof, Frieder Braunschweig, Lars H. Lund, Gianluigi Savarese   +12 more
wiley   +1 more source

Efficiency of individual dosage of digoxin with calculated concentration

, 2014
Li Zhao,1,* Peng Yang,2,* Pengmei Li,1 Xiaoxing Wang,1 Wangjun Qin,1 Xianglin Zhang1 1Department of Pharmacy, 2Department of Cardiology, China-Japan Friendship Hospital, Beijing, People’s Republic of China *These authors contributed equally to ...
Zhao L, Yang P, Wang XX, Zhang XL, Li PM, Qin WJ   +5 more
core  

Induction of cytochrome P450 2C9 and P‐glycoprotein activity by antiseizure medications: A systematic review and network meta‐analysis

Epileptic Disorders, EarlyView.
Abstract Objectives Antiseizure medications (ASMs) can induce the activity of drug‐metabolizing enzymes and drug transporters, including cytochrome P450 (CYP)2C9 and P‐glycoprotein (P‐gp). Our objective was to comparatively assess the effects of ASMs on exposure to clinical CYP2C9 and P‐gp substrates.
Hagar Cohen, Nahawand Bahash, Tomer Ben‐Shushan, Ilan Matok, Sara Eyal   +4 more
wiley   +1 more source

Phase II trial of second-line erlotinib and digoxin for nonsmall cell lung cancer (NSCLC)

, 2011
Fadi Kayali, Muhamad A Janjua, Damian A Laber, Donald Miller, Goetz H KloeckerUniversity of Louisville, James Graham Brown Cancer Center, Louisville, KY, USABackground: In vitro digoxin sensitizes cancer cells to the induction of apoptosis by ...
Muhamad A Janjua, Donald Miller, Damian A Laber, Goetz H Kloecker, Fadi Kayali   +4 more
core